Lilly and Novo Are Reportedly Near a Deal, Offering $149 GLP-1s in Return for Coverage in Medicare

And Pfizer suggests that its MFN deal will leave a mark: “We expect a dilutive impact to our 2026 financial outlook.”

Brian Reid

Nov 5, 2025